News | April 14, 2011

Interim Results From Imaging Agent Trial Unveiled

April 14, 2011 – Interim results from a randomized study on the impact of a SPECT imaging system on clinical management and diagnosis of adult patients who exhibit signs or symptoms of parkinsonian syndromes (PS) have been released. The study used GE Healthcare’s DaTscan system.

The results, presented at the 2011 American Academy of Neurology Meeting, are an important step in documenting the value of the system as an adjunct diagnostic tool for use in differentiating between PS and disorders such as essential tremor (ET) that have similar symptoms.

DaTscan was approved by the U.S. Food and Drug Administration (FDA) in January 2011. It is a radiopharmaceutical imaging agent that works by binding to dopamine transporters (DaT) in the brain.

This multi-center, open label, randomized clinical trial compared the management, diagnosis, confidence of diagnosis (CoD), and quality of life (QoL) at four, 12 weeks and 52 weeks after randomization to either undergo DaTscan SPECT imaging (N=1331 randomized; 119 dosed and scanned) or not (N=136). The full study will evaluate patients through one year from baseline. Interim results showed more patients in the DaTscan group had changes from baseline (pre-DaTscan) diagnosis and their physicians had a higher mean CoD compared with the control group at both four and 12 weeks post-randomization. Additionally, in patients with a management plan at baseline (N=113 DaTscan and 125 control), significantly more DaTscan patients had management changes 12 weeks after randomization (49 percent vs. 31 percent) compared to the control group (p=0.004).

“Interim clinical results show that DaTscan can be useful in providing objective evidence for patients with diagnostic uncertainty,” said Frederick Weiland, M.D., Sutter Medical Group Diagnostic Medical Imaging co-director of nuclear medicine. “In addition, physicians of patients participating in the study had more confidence in their diagnosis and recommended treatment when they had a DaTscan image.”

Fifty thousand to 60,000 new cases of Parkinson’s disease (PD), a form of PS, are diagnosed in the United States each year, but an accurate diagnosis can take up to six years. Many people mistakenly attribute the first symptoms of PD to the normal aging process, and many have misconceptions about diagnosis.

Use of DaTscan imaging may enable appropriate management for adult patients who have signs or symptoms of PS, through timely, appropriate diagnosis. PS occurs when the brain does not get enough dopamine to perform certain functions. This affects the ability of the brain to control movement and other muscle functions.

For more information: www.datscan.com, www.gehealthcare.com

Related Content

Clinical Trial Testing Topical Gel to Reduce Breast Density
News | Breast Density | June 19, 2018
Women with dense breast tissue soon might be adding a new product to their skincare routine to help them fight breast...
New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Report Finds Identifying Patients for Lung Cancer Screening Not So Simple
News | Lung Cancer | June 18, 2018
New findings in the current issue of The American Journal of Managed Care suggest that getting the right patients to...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Accuray TomoTherapy System Beneficial in Two Total Body Irradiation Studies
News | Radiation Therapy | June 13, 2018
Recently published data from two new studies demonstrate the benefits of Accuray’s TomoTherapy System in the delivery...
Women More Likely to Use Other Preventive Health Services Following Mammography
News | Mammography | June 13, 2018
Medicare beneficiaries who undergo breast cancer screening with mammography are more likely than unscreened women to...
Reduced hippocampal volume on MRI

This figure shows reduced hippocampal volume over the course of 6 years as seen on progressive volumetric analysis and also coronal MRI evaluations (arrows).Progressive volume loss in the mesial temporal lobe on MRI is a characteristic imaging feature of AD. This patient was a case of Alzheimer’s Dementia.

 

News | Neuro Imaging | June 12, 2018
According to a UCLA Medical Center study, a new technology shows the potential to help doctors better determine when...
High Prevalence of Atherosclerosis Found in Lower Risk Patients
News | Magnetic Resonance Imaging (MRI) | June 08, 2018
Whole-body magnetic resonance angiography (MRA) found a surprisingly high prevalence of atherosclerosis in people...
Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
Emerging Trends in Nuclear Medicine
Feature | Nuclear Imaging | June 04, 2018 | By Jeff Zagoudis
Nuclear imaging and its various modalities have long played an important role in the diagnosis and treatment of numer
Overlay Init